Trial Profile
Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Heart failure; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms BADDHY
- 27 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jan 2010 Additional trial lead investigator identified as reported by ClinicalTrials.gov.
- 14 Jan 2010 Planned end date changed from 1 Apr 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.